Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Net Cash Flow (2016 - 2022)

Edesa Biotech's Net Cash Flow history spans 10 years, with the latest figure at -$5.6 million for Q3 2022.

  • For Q3 2022, Net Cash Flow fell 4137.65% year-over-year to -$5.6 million; the TTM value through Sep 2022 reached -$655330.0, down 230.11%, while the annual FY2025 figure was $9.7 million, 326.4% up from the prior year.
  • Net Cash Flow for Q3 2022 was -$5.6 million at Edesa Biotech, down from -$3.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $10.0 million in Q1 2022 and bottomed at -$5.6 million in Q3 2022.
  • The 5-year median for Net Cash Flow is -$694843.0 (2018), against an average of $146755.6.
  • The largest annual shift saw Net Cash Flow surged 515.32% in 2019 before it tumbled 11201.23% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$382346.0 in 2018, then crashed by 219.61% to -$1.2 million in 2019, then increased by 16.8% to -$1.0 million in 2020, then crashed by 94.97% to -$2.0 million in 2021, then tumbled by 183.94% to -$5.6 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Net Cash Flow are -$5.6 million (Q3 2022), -$3.0 million (Q2 2022), and $10.0 million (Q1 2022).